Fjarde AP Fonden Fourth Swedish National Pension Fund Increases Stake in Regeneron Pharmaceuticals, Inc. $REGN

Fjarde AP Fonden Fourth Swedish National Pension Fund increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 18.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 39,452 shares of the biopharmaceutical company’s stock after buying an additional 6,200 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Regeneron Pharmaceuticals were worth $20,712,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in REGN. Activest Wealth Management grew its holdings in Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 21 shares in the last quarter. Costello Asset Management INC purchased a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth $27,000. Saudi Central Bank purchased a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth $27,000. Colonial Trust Advisors acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter worth $32,000. Finally, SouthState Corp increased its holdings in Regeneron Pharmaceuticals by 550.0% in the first quarter. SouthState Corp now owns 52 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 44 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $585.31 on Tuesday. The firm’s fifty day simple moving average is $576.55 and its 200-day simple moving average is $562.59. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $943.27. The stock has a market capitalization of $62.04 billion, a price-to-earnings ratio of 14.75, a PEG ratio of 1.80 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts’ consensus estimates of $8.43 by $4.46. The firm had revenue of $3.68 billion during the quarter, compared to analysts’ expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. Regeneron Pharmaceuticals’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $11.56 EPS. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals’s payout ratio is 8.87%.

Analysts Set New Price Targets

A number of analysts have issued reports on REGN shares. Argus downgraded Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, June 30th. BMO Capital Markets raised their target price on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a research report on Monday, August 4th. Sanford C. Bernstein boosted their target price on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 27th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $850.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, October 23rd. Finally, Guggenheim increased their price target on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $802.35.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.